OKYO Pharma Limited (NASDAQ:OKYO) Short Interest Update

OKYO Pharma Limited (NASDAQ:OKYO) was the recipient of a significant growth in short interest in March. As of March 31st, there was short interest totalling 182,500 shares, a growth of 259.3% from the March 15th total of 50,800 shares. Approximately 1.0% of the shares of the company are short sold. Based on an average daily trading volume, of 183,900 shares, the short-interest ratio is presently 1.0 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in OKYO Pharma stock. Barclays PLC purchased a new stake in shares of OKYO Pharma Limited (NASDAQ:OKYO) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 25,000 shares of the company’s stock, valued at approximately $46,000. Barclays PLC owned 0.09% of OKYO Pharma as of its most recent SEC filing. Institutional investors and hedge funds own 2.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright lifted their target price on shares of OKYO Pharma from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Friday, March 22nd.

OKYO Pharma Price Performance

Shares of OKYO stock traded up $0.02 during trading hours on Friday, reaching $1.39. 8,658 shares of the company were exchanged, compared to its average volume of 168,104. OKYO Pharma has a fifty-two week low of $0.92 and a fifty-two week high of $3.25. The stock’s fifty day moving average is $1.45 and its two-hundred day moving average is $1.63.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.